Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2021-07-29
Target enrollment:
Participant gender:
Summary
To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel
and gemcitabine in patients with previously untreated pancreatic cancer.